A Phase II, Double-Blind Trial of Recombinant Human Nerve Growth Factor for Treatment of HIV-Associated Sensory Neuropathy

Clinical Trial ID NCT00000842

PubWeight™ 4.56‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00000842

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 2012 1.69
2 Severity of HIV-associated neuropathy is associated with plasma HIV-1 RNA levels. AIDS 2002 1.68
3 A phase II trial of nerve growth factor for sensory neuropathy associated with HIV infection. AIDS Clinical Trials Group Team 291. Neurology 2000 1.35
4 Nerve growth factor study opens. GMHC Treat Issues 1996 0.75
5 Hyperthermia study finds little effect. GMHC Treat Issues 1995 0.75
6 Nerve growth factor: major trial canceled, revived after protest. AIDS Treat News 1995 0.75
7 Potential therapy for painful neuropathy. PI Perspect 1995 0.75
Next 100